• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconMerck

Merck

SuccessMerck exec says Chernobyl changed the course of her life after her father begged her to leave nuclear physics on his deathbed
By Orianna Rosa RoyleJune 17, 2025
ConferencesQueens of influence: Meet the women shaping Europe’s future
By Fortune EditorsMay 23, 2025
HealthPharma giant Merck expects Trump’s tariffs to cost the company $200 million
By Maia Anderson and Healthcare BrewApril 25, 2025
Cancer vaccination, conceptual illustration
HealthPersonalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
By Lindsey LeakeFebruary 7, 2025
CommentaryThe faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
By Jeffrey Sonnenfeld and Steven TianFebruary 5, 2025
Close-up of cast metal sign for the pharmaceutical company Merck
HealthMerck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
By Hallie SteinerFebruary 4, 2025
A nurse administers a dose of the HPV vaccine at an Illinois health clinic in 2018.
HealthMerck’s $8 billion cancer vaccine faces first U.S. jury trial
By Bloomberg and Peter BlumbergJanuary 27, 2025
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
HealthMerck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
By Lindsey LeakeDecember 20, 2024
TechMerck snags Chinese obesity drug in nearly $2 billion deal
By Robert Langreth and BloombergDecember 18, 2024
Just 25% of people at high risk of pneumococcal disease—children younger than 2, adults older than 64, and those with certain chronic health conditions such as diabetes—have been immunized, according to an August 2024 survey by the National Foundation for Infectious Diseases.
HealthPneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination
By Lindsey LeakeOctober 22, 2024
LeadershipHow Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4 billion dispute
By John KellOctober 22, 2024
Boston Scientific headquarters as pictured on Jan. 19, 2007. The company acquired device-maker Axonics Inc. for $2.7 billion on Monday.
HealthJ&J, Merck, Boston Scientific go on $6.4B buying spree
By Fiona Rutherford and BloombergJanuary 8, 2024
LeadershipFormer Merck CEO Ken Frazier on the responsibility of CEOs to uphold principles despite politics
By Fortune EditorsNovember 9, 2023
HealthU.S. cancer patients face nationwide shortages of life-saving chemo drugs as ‘race to the bottom’ makes their production unprofitable
By Christiaan HetznerOctober 28, 2023
Merck & Co. Chief Executive Officer Kenneth Frazier Interview
LeadershipKen Frazier, long one of the few Black Fortune 500 CEOs, is fighting against ‘the vestiges of the way this country was run for 400 years’
By Trey WilliamsOctober 3, 2023
1
  • 1
  • 2
  • 3
  • 4
  • 5
...9
Most Popular
Success
After decades in the music industry, Pharrell Williams admits he never stops working: ‘If you do what you love everyday, you’ll get paid for free'An image of a popular article
By Emma BurleighFebruary 3, 2026
Politics
Peter Thiel warns the Antichrist and apocalypse are linked to the ‘end of modernity’ currently happening—and cites Greta Thunberg as a driving exampleAn image of a popular article
By Nick LichtenbergFebruary 4, 2026
Investing
Ray Dalio warns the world is ‘on the brink’ of a capital war of weaponizing money—and gold is the best way for people to protect themselvesAn image of a popular article
By Sasha RogelbergFebruary 4, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.